In this SlideShare, we explore the potentially game-changing diagnostic and monitoring method for cancer patients, known as Liquid Biopsy. A simple and non-invasive alternative to conventional surgical biopsies, liquid biopsy enables doctors to discover a range of information about a patient's tumor through a simple blood sample. We will also cover on how Intervenn's unique glycoproteomics & AI analysis platform is being developed to detect colorectal pre-cancer.

1. Non-Invasive Diagnosis for Cancer Patients
For more info, contact us: xeraya@xeraya.com
Follow us: @xerayacapital
www.xeraya.com
Liquid Biopsy in Oncology
September 2022. © Xeraya Capital.
1

2. Liquid Biopsy in Oncology
Content Overview
• What is Liquid Biopsy?
• Potential Applications in Clinical
Oncology
• Recap on Biopsy
• Liquid Biopsy vs Tissue Biopsy
• Vast Potential with Analytes
• Key Market Figures & Growth
• Glycoproteomics & AI
• Intervenn’s Advanced Adenoma
Pre-Cancer Detection
September 2022. © Xeraya Capital.
2

3. What is Liquid Biopsy?
Liquid biopsy is a type of test
done on a patient’s blood
sample to look for cancer
cells (or pieces of DNA) from
a tumor that are circulating
in the blood.
It is a simple and non-invasive
alternative to conventional surgical
biopsies, enabling doctors to
discover a range of information
about a tumor through a simple
blood sample.
September 2022. © Xeraya Capital.
3
Credit: NIH Director’s Blog (2018)
Source: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/liquid-biopsy

4. Source: https://www.roche.com/stories/liquid-biopsy-in-oncology
Credit: Remon, et. al., Springer (2020)
September 2022. © Xeraya Capital.
4
1. A doctor or trained medical
personnel would extract as little as
5 ml of the patient’s blood.
2. The blood sample is then ‘spun
down’ to get 2 ml of plasma.
3. Analytes would be extracted and is
then analyzed for tumor or cancer
properties.
Liquid Biopsy in a nutshell

5. Potential Liquid Biopsy Applications
September 2022. © Xeraya Capital.
5
Source: https://www.cancer.gov/publications/dictionaries/cancer-terms/def/liquid-biopsy
DETECTION
Liquid biopsies can be used to
detect cancer at an early stage
due to high sensitivity.
TREATMENT
Liquid biopsies helps doctors
plan cancer treatment &
determine if it is working.
STUDY
Multiple blood samples taken
over time helps doctors
understand molecular changes.

6. Comparing Biopsy Methods
Conventional Biopsy vs Liquid Biopsy
September 2022. © Xeraya Capital.
6

7. Recap: What is a Biopsy?
A biopsy is a sample of tissue
taken from the body in order
to examine it more closely.
Biopsies are most often done
to look for cancer.
It is a recommended procedure
when an initial test suggests an
area of tissue in the body isn't
normal. Depending on the area,
the procedure is usually done
using a needle or surgical incision.
Source: https://www.webmd.com/cancer/what-is-a-biopsy
Credit: Mayo Clinic
September 2022. © Xeraya Capital.
7
An example of a bone marrow biopsy performed on
the back of a patient’s hipbone using a long needle.

8. New vs Old: Liquid Biopsy vs Tissue Biopsy
September 2022. © Xeraya Capital.
8 Source: https://molecular-cancer.biomedcentral.com/articles/10.1186/
s12943-022-01543-7
Over the past decade, conventional
techniques for diagnosing & monitoring
cancers are being replaced by liquid
biopsy which is non-invasive.
Liquid biopsies can drastically change
the field of clinical oncology:
1. Ease of sampling
2. Continuous sampling & monitoring
3. Personalized cancer therapy
4. Screening therapeutic resistance
Credit: Lone, et. al., Molecular Cancer (2022)

9. Key Figures in the Liquid Biopsy market
September 2022. © Xeraya Capital.
Liquid Biopsy
Market to Reach
USD 7.96 billion by
2030
- Increase from USD
33.49 million in 2020
- CAGR of 23.4%
(2021-2030)
- LB increasingly
popular among
patients
Vision Research Reports
Technology: NGS has
largest revenue share
Multi-gene-parallel
analysis (next-gen
sequencing) can detect
59% of stage 1/2 lung
cancer patients
Fastest CAGR for
Exosomes & Micro-
vesicles
miR Scientific's single
urine sample can detect
prostate cancer with an
accuracy of 90%
Source: Vision Research Reports, BioSpace
9
Key Insights:
- North America has
largest revenue share
with 51% in 2020 due to
greater investments
- Numerous emerging
biotech companies
developing LB tests
- First LB test approved
by the FDA in 2013,
with more approvals
expanded in 2020
American Society of
Clinical Oncology

10. 2013: CellSearch® CTC (circulating tumor cells) to monitor breast, colon & prostate
cancers
2016: Roche cobas EGFR (epidermal growth factor receptor) gene mutations to
identify non-small cell lung cancer (NSCLC)
2020: Guardant360 CDx can detect changes in >60 different genes (genomic
alterations) causing solid tumors; approved as companion diagnostic
2020: FoundationOne Liquid CDx can identify alterations in >300 genes relevant in
lung, prostate, colorectal, ovarian & breast cancers; all as companion diagnostic
FDA-Approved Liquid Biopsy Tests
September 2022. © Xeraya Capital.
10 Source: https://ascopost.com/issues/october-10-2021/the-evolution-of-
liquid-biopsy-in-cancer-care/

11. Vast Potential in
Liquid Biopsy
Tapping Into the Potential of Analytes
September 2022. © Xeraya Capital.
11

12. September 2022. © Xeraya Capital.
12
A single liquid biopsy can
provide various analytes isolated
from the blood, allowing them to
analyze a wide variety of
information regarding a
patient's tumor or cancer.
Each analyte has a specific
application in a cancer patient's
diagnosis, monitoring and
treatment.
Analytes Galore: Liquid Biopsy’s Vast Potential
Source: https://molecular-cancer.biomedcentral.com/articles/10.1186/
s12943-022-01543-7
Credit: Lone, et. al., Molecular Cancer (2022)

13. Tackling Complexity with AI
With the vast number of
analytes from a single liquid
biopsy sample, some
companies are leveraging on
artificial intelligence.
Protein glycosylation is a complex
and diverse subject. Within the last
decade, glycoproteomic signatures
can reveal much about genetic
defects, tumor and inflammation in
cancer patients.
Credit: Fernandes, et. al. (ResearchGate, 2020)
September 2022. © Xeraya Capital.
13
AI-powered software can utilize deep learning to
automate the analysis of various complex
biomarkers & decode the glycoproteome quickly
and effectively.
Source: https://intervenn.com/

14. Protein Glycosylation & Glycans
Glycans are synomymous to
polysaccharides (compounds
that are made of many sugar
molecules linked glycosically).
Glycosylation is the process of
attaching sugar molecules to a variety
of bio-materials such as proteins,
lipids and RNA. One such example is
‘protein-folding’; making polypeptide
chains become biologically active for
various cell functions.
September 2022. © Xeraya Capital.
14
Credit: Shental-Bechor & Levy (PNAS, 2008)
Source: https://intervenn.com/
Glycosylation is essential for normal cell &
organ functions, and alterations are usually
associated with cancer.

15. Detecting Colon Cancer
The Right Timing for Diagnosis: An Unmet Need
September 2022. © Xeraya Capital.
15

16. Screening Adenomatous Polyps
Colon cancer begins in the large
intestine (colon), the final part of
the digestive tract. It is the 3rd
leading cancer in the world today.
Colonoscopies are often overused in
early screening (18 million procedures/
year) where >90% will find no
abnormalities (most polyps are too small
to be regarded as imminent cancer
potential). Adeno-carcinoma on the
other hand would indicate that screening
is too late.
Source: https://www.mayoclinic.org/diseases-conditions/colon-
cancer/symptoms-causes/syc-20353669
Credit: GastroIntestinalAtlas.com
September 2022. © Xeraya Capital.
16
Colon cancer can be completely avoided
with screening for adenomatous polyps
since all cancers arise from polyps.

17. Adenoma Pre-Cancer Screening by Intervenn
September 2022. © Xeraya Capital.
17
Intervenn Biosciences is
currently developing CRC
(colorectal cancer) screening
tests focusing on adenoma
pre-cancer detection.
By leveraging on their proprietary
AI platform, Intervenn’s technology
is currently 2-4 times more
sensitive in detecting advanced
adenoma sequences within a
patient’s blood sample.
Credit: Intervenn
Intervenn's Advanced Adenoma can detect
pre-malignancy via well-characterized
epigenetic & glycosylation alterations.
Source: https://intervenn.com/

18. • Liquid biopsy is a type of test done on a patient’s blood
sample to look for cancer cells (or pieces of DNA) from a
tumor that are circulating in the blood.
• This simple and non-invasive diagnostic tool is becoming an
increasingly popular alternative to conventional surgical
biopsies.
• Liquid biopsy is enabling doctors to discover a range of
information about a tumor through a simple blood sample.
• Leveraging AI to analyze complex glycosylation, Intervenn’s
platform is able to perform pre-cancer detection.
Conclusion
September 2022. © Xeraya Capital.
18

19. By xeraya capital
For more info, contact us: xeraya@xeraya.com
Follow us: @xerayacapital
www.xeraya.com
September 2022. © Xeraya Capital.
19